New trial aims to reduce urinary side effects in prostate cancer treatment
NCT ID NCT07300566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a more targeted (focal) radiation boost can better preserve urinary quality of life compared to standard whole gland treatment in men with intermediate- or high-risk prostate cancer. About 58 participants will receive either focal or whole gland high dose-rate brachytherapy plus external beam radiation. The main goal is to measure changes in urinary function over 24 months using a standard questionnaire.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
London Health Sciences Centre, Verspeeten Family Cancer Centre
London, Ontario, N6A 5W9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?